


CLINICAL OUTCOMES AND ECONOMIC EVALUATION OF ORITAVANCIN THERAPY: A REAL-WORLD STUDY

S. ROLDÁN MARTÍNEZ¹, M. CORREA BALLESTER¹, E. MONTE BOQUET¹, D. GALLEN SORIA¹, J.M. CAMPOS BARRACHINA¹, B. ARNAU BLASCO¹, M. CHIVI TRULL¹, L. ESCOBAR HERNÁNDEZ¹, M. RODENAS ROVIRA¹, J. GARCÍA PELLICER¹, J.L. POVEDA ANDRÉS¹

¹Pharmacy Service. Hospital Universitari i Politècnic La Fe. Valencia.

Background and Importance



Long-acting lipoglycopeptide active against multidrug-resistant Gram-positive cocci.



Enable single-dose therapy and potential reduction in hospital stay and costs.

Objectives



To characterize real-world oritavancin use and evaluate its economic impact when administered at hospital discharge.


Materials and Methods




Retrospective observational study



All patients treated with oritavancin (September 2023–July 2025) in a tertiary hospital.



Demographic variables collected: age and sex.



Clinical data: type of infection, isolated microorganism, indication, and dosage.



Outcomes assessed: clinical cure, microbiological results, 30-day mortality, and adverse events.



Healthcare impact evaluated: hospital length of stay and economic cost.

Conclusions and relevance

1


Oritavancin showed high clinical cure rates and a favorable safety profile, with few adverse events, although infusion-related reactions require monitoring.

2

Administration at hospital discharge allowed substantial cost savings by reducing prolonged inpatient stays.

3

Further studies are needed to define its role in antimicrobial stewardship and healthcare resource optimization.



Results




28 infection episodes in 25 patients




80% male, median age 54 years




Main indications were SSTIs (64.3%) and osteoarticular infections (28.6%).



Most frequent pathogens:



Clinical cure was achieved in 71.4%, with 14.3% relapse and no 30-day mortality.



Adverse events were uncommon (7.1% of cases), including one severe infusion-related reaction.

Treatment cost	€1,342–€2,237
Avoided hospitalization costs (per patient)	€4,550–€27,300
Estimated savings	€30,074–€337,459